A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

Inclusion Criteria: * Age between 18 and 70 years, with no gender restrictions; * Patients with CLL/SLL who meet the iwCLL2018 diagnostic criteria; * Indications for treatment * ECOG performance score of 0-2; * Patients are untreated or have not received standardized treatment * Before the trial screening, the subject or their legal representative voluntarily signs a written informed consent form, indicating that they understand the purpose of the study and the necessary research steps, and are able to comply with the protocol and follow-up. Exclusion Criteria: * Has been diagnosed or treated for malignancies other than CLL (including active central nervous system lymphoma) within the past year; * there is clinical evidence of Richter transformation; * Participant cannot receive or plan to receive another treatment during study participation * Other conditions that the investigator considers inappropriate for participation